| Code | CSB-RA021334MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ADU-1805, targeting signal regulatory protein alpha (SIRPα), a cell surface receptor that plays a critical role in regulating innate immunity. SIRPα functions as an inhibitory receptor that binds to CD47, a "don't eat me" signal expressed on cell surfaces, thereby preventing phagocytosis by macrophages. This interaction represents a key immune checkpoint mechanism that tumor cells exploit to evade immune surveillance, making SIRPα an important target in cancer immunotherapy research. Dysregulation of the SIRPα-CD47 axis has been implicated in various malignancies, where tumor cells overexpress CD47 to avoid macrophage-mediated destruction.
ADU-1805 is a clinical-stage therapeutic antibody designed to block the SIRPα-CD47 interaction, promoting tumor cell phagocytosis and enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating SIRPα biology, exploring immune checkpoint mechanisms, and studying potential therapeutic strategies in oncology and immunology research. It enables investigation of macrophage function, tumor microenvironment dynamics, and innate immune modulation across various experimental models.
There are currently no reviews for this product.